biuro@scopefluidics.com +48 22 376 21 14
biuro@scopefluidics.com +48 22 376 21 14
biuro@scopefluidics.com +48 22 376 21 14

RAPORT ESPI 13/2022 | 03-08-2022 | Zbycie 100% udziałów Curiosity Diagnostics sp. z o.o. na rzecz Bio-Rad Laboratories Inc.

Previous PostNext Post

Related Posts

16.01.2026

Scope Fluidics Fellowship is back – 2nd edition coming soon!

0
08.01.2026

Scope Fluidics enters into a distribution agreement in the Turkish market

0
01.12.2025

Scope Fluidics Q1–Q3 2025 Results: Secures a stronger cash position and appoints a leading transaction advisor

0